Propulsion of Sarcopenia Clinical Trial Pipeline as Novel and Extensive 8+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, the Sarcopenia Pipeline constitutes 8+ key companies continuously working towards developing 10+ Sarcopenia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Sarcopenia Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Sarcopenia NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

To explore more information on the latest breakthroughs in the Sarcopenia Pipeline treatment landscape of the report, click here @ Sarcopenia Pipeline Outlook- https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Sarcopenia Pipeline Report
• DelveInsight's Sarcopenia Pipeline analysis depicts a robust space with 8+ active players working to develop 10+ pipeline treatment therapies.
• The leading companies working in the Sarcopenia Market include Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others.
• Promising Sarcopenia Pipeline Therapies in the various stages of development include REGN1033 (SAR391786), bimagrumab, Comparator: MK-0773, Astaxanthin formulation, LPCN 1148, and others.
• On August 2023, MyMD Pharmaceuticals Inc. announced a study of phase 2 clinical trials for MYMD-1 600MG. The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines.

Sarcopenia Overview
Sarcopenia is a musculoskeletal disease in which muscle mass, strength, and performance are significantly compromised with age. Sarcopenia most commonly affects elderly and sedentary populations and patients who have comorbidities that affect the musculoskeletal system or impair physical activity.

For further information, refer to the detailed Sarcopenia Unmet Needs, click here for Sarcopenia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sarcopenia Emerging Drugs Profile
• Sarconeos (BIO101): Biophytis
• MYMD-1: MyMD Pharmaceuticals

Sarcopenia Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the therapies for Sarcopenia. The companies which have their Sarcopenia drug candidates in the most advanced stage, i.e. phase III include, Biophytis.

Request a sample and discover the recent advances in Sarcopenia Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Sarcopenia Segmentation- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sarcopenia Drugs and Companies
• REGN1033 (SAR391786): Regeneron Pharmaceuticals
• Bimagrumab: Novartis Pharmaceuticals
• LPCN 1148: Lipocine Inc.

Sarcopenia Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Sarcopenia Therapeutics Market include-
Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others.

Dive deep into rich insights for drugs for Sarcopenia Pipeline, click here @ Sarcopenia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Sarcopenia Pipeline Report
• Coverage- Global
• Companies- Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others.
• Therapies- REGN1033 (SAR391786), bimagrumab, Comparator: MK-0773, Astaxanthin formulation, LPCN 1148, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Sarcopenia Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Sarcopenia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sarcopenia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Sarconeos (BIO101): Biophytis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MYMD-1: MyMD Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PF-1801: PhaseBio Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Sarcopenia Key Companies
21. Sarcopenia Key Products
22. Sarcopenia- Unmet Needs
23. Sarcopenia- Market Drivers and Barriers
24. Sarcopenia- Future Perspectives and Conclusion
25. Sarcopenia Analyst Views
26. Sarcopenia Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.